18-Methylaminocoronaridine
18-Methylaminocoronaridine (18-MAC) is a synthetic derivative of the naturally occurring alkaloid ibogaine. It belongs to the class of iboga alkaloids and has been studied for its potential therapeutic effects, particularly in the treatment of substance use disorders.
Chemical Structure and Properties[edit]
18-Methylaminocoronaridine is structurally related to ibogaine, with the primary difference being the addition of a methylamino group. This modification is believed to influence its pharmacological profile and potentially reduce some of the adverse effects associated with ibogaine.
Pharmacology[edit]
18-MAC acts on multiple neurotransmitter systems, including the dopamine, serotonin, and glutamate systems. It is thought to exert its effects by modulating these neurotransmitter pathways, which are implicated in addiction and neuroplasticity.
Mechanism of Action[edit]
The exact mechanism of action of 18-MAC is not fully understood. However, it is believed to interact with NMDA receptors, sigma receptors, and nicotinic acetylcholine receptors. These interactions may contribute to its potential anti-addictive properties.
Therapeutic Potential[edit]
Research on 18-Methylaminocoronaridine has primarily focused on its potential use in treating substance use disorders, including opioid addiction, cocaine addiction, and alcohol dependence. Preclinical studies have shown promising results, but clinical trials are necessary to establish its efficacy and safety in humans.
Side Effects and Safety[edit]
As with other iboga alkaloids, there are concerns about the safety profile of 18-MAC. Potential side effects may include cardiotoxicity, neurotoxicity, and hallucinogenic effects. Further research is needed to fully understand the risk-benefit profile of this compound.
Legal Status[edit]
The legal status of 18-Methylaminocoronaridine varies by country. In some jurisdictions, it may be classified under the same regulations as ibogaine, while in others, it may not be specifically regulated.
See Also[edit]
- Ibogaine
- Substance use disorder
- Neurotransmitter
- NMDA receptor
- Sigma receptor
- Nicotinic acetylcholine receptor
References[edit]
External Links[edit]
 | This medical article is a stub. You can help WikiMD by expanding the page. |
Sponsored Health Resource
W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
Medical weight loss NYC | Affordable GLP-1 injections NYC | Budget GLP-1 weight loss shots Philadelphia | New Jersey medical weight loss | NYC medical weight loss | Philadelphia medical weight loss | Sleep clinic NYC | W8MD's Philadelphia GLP-1 doctor | Weight loss prescriptions NYC
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
